Regeneron

News

Dupixent nears EU approval for rare skin disease prurigo nod...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease.

News

And then there were none: Regeneron cans last late-stage NGF...

The hope that nerve growth factor (NGF) inhibitors could be an alternative to opioid for pain relief has finally been extinguished with the news that Regeneron had abandoned the last drug i

News

Regeneron's Inmazeb named Galien's Best Biotech Product

The Galien Foundation, which acknowledges “extraordinary scientific innovations that improve the human condition”, has awarded its

News

abstract shapes, bone structure, 3d render, bone

Ipsen faces yet another delay for rare disease drug in US

Less than a week before Ipsen's palovarotene was due to go in front of an FDA advisory committee, the meeting has been called off following a request by the regulator for more data.

News

Weak data for Fasenra undermine AZ's ambitions for the drug

AstraZeneca's IL-5 inhibitor Fasenra is already making blockbuster sales from its use in eosinophilic asthma, but the drugmaker's efforts to expand its label keep running into difficulties.

News

FDA clears Dupixent as first drug for rare skin disorder

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin di

Dupixent nears EU approval for rare skin disease prurigo nod...

And then there were none: Regeneron cans last late-stage NGF...

Regeneron's Inmazeb named Galien's Best Biotech Product

Ipsen faces yet another delay for rare disease drug in US

Weak data for Fasenra undermine AZ's ambitions for the drug

FDA clears Dupixent as first drug for rare skin disorder

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Regeneron

Editor's Picks